{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).","groups":[{"description":"Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG000","title":"Abiraterone Acetate + Prednisone (AAP)"},{"description":"Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG001","title":"Placebo"}],"populationDescription":"Data was not reported as non-compartmental analysis was not performed due to sparse sampling.","reportingStatus":"POSTED","timeFrame":"Up to Cycle 5, Day 1","title":"Elimination Half-Life (t1/2)","type":"SECONDARY"}